comprehensive -WSS

comprehensive

author：leisure time 2025-09-06 01:55:40 - browse：13

Photo illustration of a checkbook wrapped with lock and chain – hospital and investment coverage from STAT — Alex Hogan/STAT

Hospitals once dove headfirst into venture capital with splashy headlines and attention-grabbing numbers. Now, in an era of flattened margins and exceedingly uncertain returns, many health systems are quietly pulling back.

NewYork-Presbyterian’s venture firm, once managing roughly $40 million in assets, was essentially dissolved, two former employees said, with leaders punting it from the system’s strategy division to innovation, then from innovation to the investment office — a spokesperson described it as being “integrated” into the broader strategy. PitchBook data show no investments after 2020.

Advocate Health Enterprises, meanwhile, the venture firm of a 67-hospital system based in Charlotte, N.C., has lost at least six employees within the past year, including its president, from a staff that once included about a dozen people.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Key House panel plots a new health care package

WSS

At Orexo, a ‘turning point’ for everything but digital health

Why hospitals are withdrawing from US News rankings

Data integrity in scientific journals requires "effort" by publishers, institutions

Medicare to cover more brain scans for Alzheimer’s patients

Key House panel plots a new health care package

Venture capitalist Bob Kocher on the state of digital health

entertainment

comprehensive

entertainment

Bright Health sells Medicare Advantage business to Molina

AI can’t replace a physician’s gut feeling

Hepatitis C has a cure — but many Americans still lack access to it

Google and Epic fight stronger regulation of AI in health care

Hollywood unions extend contract negotiations for actors

Startup Neumora takes a novel depression drug to Phase 3

Novavax promises a turnaround & Lilly roils the obesity market

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Jerome Adams on the need for new antivirals for Covid

Medicare has a new plan to address drug shortages

explore

STAT Virtual Event: The State of Biosimilars: What to Watch

Sanofi seeks simpler, safer CRISPR sickle cell cure

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

At Orexo, a ‘turning point’ for everything but digital health

At Orexo, a ‘turning point’ for everything but digital health

Key House panel plots a new health care package

focus

focus

focus

knowledge